Seoul-based IVI Partners With Indian Shantha Biotechnics For Low-Cost Cholera Vaccine Licensed in India
This article was originally published in PharmAsia News
Executive Summary
SEOUL - A new oral cholera vaccine developed by Seoul-based International Vaccine Institute has been licensed to India's Shantha Biotechnics, paving the way for worldwide use of a low-cost cholera vaccine in developing countries, where most cholera cases occur, the IVI said
You may also be interested in...
Inviragen Finds New Life For Shelved Japanese Encephalitis Vaccine At State-Owned VABIOTECH
A vaccine project put on the shelf – after better-funded Intercell won regulatory approval for a rival product – has found a new home in Vietnam at a state-owned company looking to keep costs in check.
India’s Shantha Biotech Draws Interest From MNCs And Universities Alike
MUMBAI - The race to buy an equity stake in India's vaccine maker Shantha Biotechnics is taking a curious turn with a few international academic institutions and universities showing interest in the company's product pipeline and marketed vaccines
India’s Shantha Biotech Draws Interest From MNCs And Universities Alike
MUMBAI - The race to buy an equity stake in India's vaccine maker Shantha Biotechnics is taking a curious turn with a few international academic institutions and universities showing interest in the company's product pipeline and marketed vaccines